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The incidence of breast cancer is still rising, and the
disease remains largely incurable once it becomes malig-
nant. It is the most prevalent cancer in Europe and USA,
with 41,000 new cases each year in the UK [1]. Fortu-
nately we are beginning to gain insights into the origins of
breast cancer, and now know that many of the key risk
factors are related to life-styles associated with the hectic,
consumer-based trends of Western cultures. For example,
we consume more calories, eat fewer nutritive foods, and
do less exercise than our forebears, leading to early
menarche, obesity, and ingestion of fewer naturally occur-
ring compounds that quench free radicals and reduce
oxidative stress on DNA. Moreover, many women have
their first full-term pregnancies when they are older. Para-
doxically this knowledge is a reason to be optimistic about
the future, because the implication is that breast cancer is
a disease that is largely preventable; it is not common in
some Far Eastern countries although women from those
societies become prone if they migrate to the West. If we
can identify how these risk factors impact on breast devel-
opment and in particular understand the molecular
changes within breast epithelium that lead to genomic
alterations, then we have a chance to establish preventa-
tive strategies to ameliorate the disease.
José and Irma Russos’ new book on the Molecular Basis
of Breast Cancer: Prevention and Treatment tackles the
problem by following a logical path of first introducing the
disease from the epidemiological point of view, before dis-
cussing how the breast develops and becomes altered in
cancer, and how we might seek to understand it through
both in vivo and culture models. The book ends with two
chapters on possible modalities for how the disease might
be inhibited in the first place. Some of these are very inter-
esting, and I particularly liked the chapters on Epidemio-
logical considerations; the first half of the one on The
(human) breast as a developing organ, where relatively
few studies have been published in comparison to the
mouse; and the chapter on Preventive strategies, which
delves into the structure and activities of many naturally-
occurring chemopreventives as well as anti-inflammato-
ries, anti-estrogens, and other compounds that are likely to
have properties to protect against the onset of cancer.
The central idea in the book comes from the observation
that early pregnancy protects against breast cancer, and
posits that a treatment to artificially induce differentiation
within mammary epithelial cells could represent a radical
new approach to prevent much of the disease. The epi-
demiological data from which this hypothesis arises is
supported strongly by experimental observations that a
state of pregnancy induced naturally, or by estrogen/prog-
esterone treatment, or by human chorionic gonadotropin
(hCG, a hormone that stimulates ovaries to produce
higher levels of estrogen and progesterone) has a dra-
matic inhibitory effect on carcinogen-induced mammary
cancer. The authors argue a case for ectopic administra-
tion of hCG as a possible preventative strategy. However,
although this might be a neat strategy for eliminating
tumours in rats, it is rather premature to consider it as pre-
ventative in humans. The likely targets for neoplastic
genomic modifications are breast stem cells and we have
no idea how hCG might affect the behaviour of these
cells. A succession of breast cancer prevention trials
began in 1985, and it would have been good to see a dis-
cussion of these. There is no mention, for example, of the
STAR trial, which is one of the largest breast cancer pre-
ventive studies ever, examining the comparative effective-
ness of tamoxifen and raloxifene. In a book where
‘prevention’ of breast cancer features in the title, one
might have expected a broad debate on all the existing
strategies, exploring the way that they work as well.
There are several other aspects of the book that are also
rather problematic. First, with reams of new data in the lit-
erature and the resultant emergence of novel concepts, I
would expect a long textbook (448 pages) on the basis of
breast cancer to include a wide-ranging and in-depth look
at its molecular control. We know that cancer is largely
due to genomic instability that arises within populations of
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(as yet undefined) stem cells, and involves the escape of
protective apoptosis and immune surveillance mecha-
nisms, deregulated proliferation, and inappropriate sam-
pling of the environment so that tumour cells ignore
normal positional cues and thereby migrate to and survive
at distant metastatic sites. However, the contemporary
ideas on many key topics, including mechanisms of
genomic instability and telomere rescue, apoptosis avoid-
ance, cell cycle regulation in cancer, and malignant
spread, are not covered in any degree of depth in this
book; indeed, most are hardly mentioned. Currently there
are no other individual volumes that consider the basis of
breast cancer at the molecular level and so, although this
is a lavishly produced and well illustrated text in the typical
quality style of Springer-Verlag, these omissions seriously
limit its usefulness.
As one progresses through the book, it becomes apparent
that most of the chapters evolve from general overviews of
each topic into mini-reviews of different aspects of the
authors’ own work. Most of the chapters include multiple
reprints of previously published data, and the authors
present their hypotheses based on the conclusions to
their own experiments. In the absence of a reasoned dis-
cussion of this work in the light of the studies from the
many other labs working on breast cancer, the book is
rather one-dimensional.
Although preventing breast cancer is an ideal that should
always be kept in sight, there are many individuals who con-
tract the disease and therefore need to be treated. There is
no doubt that improvements in detection and surgical
methods have and will continue to reduce breast cancer
mortality. However, there will always be a significant cohort
whose disease cannot be cured surgically and for these,
their tumours require treatment using biological modalities.
This has not proved to be particularly successful and fewer
than 5% of those individuals with a recurrent metastatic
breast cancer can expect to survive more than 10 years
after detection. Many of the current strategies prolong life
by a year or so and alleviate symptoms, but what we really
need are novel therapies that eliminate primary and sec-
ondary tumours with targeted efficiency. The good news is
that understanding mechanisms of cancer progression pro-
vides new opportunities for designing smart drugs that
target specific enzymes. Anastrozole (aromatase),
trastuzumab (cErbB2), gefitinib (epidermal growth factor
receptor), and celecoxib (cyclooxygenase-2) are just a few
examples that already look very promising as novel thera-
peutics. Most of these, and why they are good drugs, are
ignored in this book, so unfortunately a critical aspect of its
aim, to look at breast cancer treatment, has been omitted.
This is an exciting time to be involved with research on
breast cancer and mammary gland biology, since novel
technologies are bringing us more information, and devel-
opments such as new mouse and cell models have
encouraged a number of biologists from diverse back-
grounds to enter the field. With the excellent prospects for
the future of breast cancer research, it would be timely to
have a thorough text on the molecular basis of breast
cancer, summarizing the situation within a single volume.
Unfortunately this new book focuses far too much on the
authors’ own work in this area and fails to examine much
of the contemporary literature. We have good reason to
hope that the next two or three decades will see a dra-
matic reduction in the number of deaths arising from
breast cancer, but there is still scope for other authors to
bring our current knowledge into focus.
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